Physician

Ankit Madan, M.B.B.S.

According to 2025 Medicare claims, Ankit Madan, M.B.B.S. (NPI: 1063791119) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is MEDSTAR MEDICAL GROUP II LLC (NPI: 1184046187; TIN: 461322238) and primary practice location at 20735-3362. Madan is affiliated with the AdvantagePoint Health Alliance - Blue Ridge, LLC (ACO ID: A4654), participating under the MSSP model.

Madan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 454 traditional Medicare patients, billed 187,032 HCPCS/CPT codes, and received $2,967,575 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,048 prescription claims across 210 beneficiaries totaling $2,013,580 in drug costs, led by Revlimid (Lenalidomide). DME data shows 12 claims. Open Payments data shows 1 records totaling $25. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $31,329 to $2,967,575. Similarly, Part D prescription costs have risen steadily, from $11,352 to $2,013,580. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,194 and ending at $1,284.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	294	477	$31,329
2018	490	1,419	$72,728
2019	505	1,521	$84,353
2020	486	1,426	$68,694
2021	435	1,253	$75,598
2022	435	8,373	$202,233
2023	446	173,780	$2,199,356
2024	454	187,032	$2,967,575

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	31	101	$11,352
2016	14	30	$8,687
2017	124	305	$255,184
2018	231	1,445	$1,819,384
2019	241	1,517	$2,479,876
2020	276	1,753	$2,941,773
2021	317	2,122	$2,874,368
2022	284	1,506	$2,699,403
2023	177	673	$1,072,624
2024	210	1,048	$2,013,580

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	83	$54,236
2019	11	66	$43,155
2020	N/R	92	$50,417
2021	N/R	60	$49,494
2022	N/R	24	$1,541
2023	N/R	27	$3,236
2024	N/R	12	$226

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	112	335	$154
96413	Administration of chemotherapy into vein, 1 hour or less	67	444	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	271	684	$105
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	106	163	$14
J7050	Infusion, normal saline solution, 250 cc	94	1,010	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	44	1,064	$633,391
Lenalidomide	Lenalidomide	26	672	$320,167
Erleada	Apalutamide	12	360	$174,061
Eliquis	Apixaban	120	5,295	$98,102
Abiraterone Acetate	Abiraterone Acetate	14	420	$56,342

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$25	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ankit Madan, M.B.B.S.?

Tedicare shows public-source Medicare data for Ankit Madan, M.B.B.S. (NPI 1063791119), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ankit Madan, M.B.B.S. have ACO affiliation data?

Ankit Madan, M.B.B.S. is shown with ACO affiliation data for AdvantagePoint Health Alliance - Blue Ridge, LLC (MSSP, ACO ID A4654).

What billing organization is linked to Ankit Madan, M.B.B.S.?

Ankit Madan, M.B.B.S. is linked to MEDSTAR MEDICAL GROUP II LLC (billing NPI 1184046187) in the available physician profile data.

Does Ankit Madan, M.B.B.S. have Open Payments data?

Ankit Madan, M.B.B.S. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.